Alasdair I Simpson, Rana Khalil, David Lockington, Kerr Brogan
{"title":"Could a Hazard Perception Test Be Useful in Training Cataract Surgeons?","authors":"Alasdair I Simpson, Rana Khalil, David Lockington, Kerr Brogan","doi":"10.1111/ceo.70068","DOIUrl":"https://doi.org/10.1111/ceo.70068","url":null,"abstract":"","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":" ","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146114917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Hidden Carbon Cost of Digital Ophthalmology: A Call for Sustainable Data Practices.","authors":"Sasha Patil, Stephenie Tiew, Susan M Carden","doi":"10.1111/ceo.70074","DOIUrl":"https://doi.org/10.1111/ceo.70074","url":null,"abstract":"","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":" ","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146114989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Phenotypic Spectrum of Early Onset Angle Closure Glaucoma in Young Indian Patients.","authors":"Suresh Kumar Yadav, Anand Kumar Pathak, Viney Gupta, Shikha Gupta","doi":"10.1111/ceo.70071","DOIUrl":"https://doi.org/10.1111/ceo.70071","url":null,"abstract":"","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":" ","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146114964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Uveal melanoma is a rare malignancy arising from uveal tract melanocytes. Definitive treatment options for primary disease include plaque brachytherapy, proton beam radiotherapy and enucleation, which provide high rates of local control, but are associated with vision impairment, reduced quality of life and unsatisfactorily high rates of metastatic relapse. In the metastatic setting, average life expectancy remains less than 2 years, despite the availability of immune checkpoint inhibitors and the more recent arrival of the T cell-engaging agent, tebentafusp. Here, we provide an update regarding the current treatment of uveal melanoma, and discuss the potential roles of novel targeted therapies, immunotherapy and neoadjuvant therapy in shaping future management.
{"title":"Uveal Melanoma Treatment: An Update.","authors":"Alison Hiong, Darvy Dang, Malaka Ameratunga, Roderick O'Day","doi":"10.1111/ceo.70070","DOIUrl":"https://doi.org/10.1111/ceo.70070","url":null,"abstract":"<p><p>Uveal melanoma is a rare malignancy arising from uveal tract melanocytes. Definitive treatment options for primary disease include plaque brachytherapy, proton beam radiotherapy and enucleation, which provide high rates of local control, but are associated with vision impairment, reduced quality of life and unsatisfactorily high rates of metastatic relapse. In the metastatic setting, average life expectancy remains less than 2 years, despite the availability of immune checkpoint inhibitors and the more recent arrival of the T cell-engaging agent, tebentafusp. Here, we provide an update regarding the current treatment of uveal melanoma, and discuss the potential roles of novel targeted therapies, immunotherapy and neoadjuvant therapy in shaping future management.</p>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":" ","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146114956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thomas J Gin, Sujan A Surendran, Sophie L Rogers, Lyndell L Lim
{"title":"Methodological Limitations in Prognostic Modelling for Refractory Vogt-Koyanagi-Harada Disease: Response.","authors":"Thomas J Gin, Sujan A Surendran, Sophie L Rogers, Lyndell L Lim","doi":"10.1111/ceo.70069","DOIUrl":"https://doi.org/10.1111/ceo.70069","url":null,"abstract":"","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":" ","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146108375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号